Snakebite Epidemic

Snakebite Epidemic The WHO reclassifies snakebites to the 'A-List' of health concerns, with only half the amount of anti-venom needed globally currently being produced .
The numbers of those killed by snakebites across Africa and southern Asia can eclipse those killed in armed conflict. Dr. Abdulrazaq G. Habib says 'only about 8% of snakebite victims [in Nigeria] go to a formal hospital.' If bitten, the patient needs to be treated with anti-venom as quickly as possible, but inadequate government supplies mean that many are faced with having to spend $200 at a pharmacy to secure any. Adding to the shortage, 'the lack of motivation to produce it, given the market base, makes it impossible for [pharmaceutical companies] to continue doing so.' as a result, some resort to traditional medicines, which Dr. Habib condemns - 'if anything, this is harmful - delay is a major predictor of death.' Unfortunately lacking the resources to produce the anti-venom domestically, Nigeria is reliant on foreign imports.

This site uses cookies. By continuing to use this site you are agreeing to our use of cookies. For more info see our Cookies Policy